Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zipalertinib by Taiho Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Zipalertinib is under clinical development by Taiho Pharmaceutical and currently in Phase III for Non-Small Cell Lung Cancer. According to...
ASTX-295 by Taiho Pharmaceutical for Malignant Pleural Mesothelioma: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Malignant Pleural Mesothelioma. According to GlobalData,...
ASTX-295 by Taiho Pharmaceutical for Glioblastoma Multiforme (GBM): Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
ASTX-295 by Taiho Pharmaceutical for Uveal Melanoma: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...
ASTX-295 by Taiho Pharmaceutical for Solid Tumor: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
TAS-0728 by Taiho Pharmaceutical for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
TAS-0728 by Taiho Pharmaceutical for Solid Tumor: Likelihood of Approval
TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
TAS-1440 by Taiho Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
TAS-1440 is under clinical development by Taiho Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Beroterkib by Taiho Pharmaceutical for Melanoma: Likelihood of Approval
Beroterkib is under clinical development by Taiho Pharmaceutical and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Beroterkib by Taiho Pharmaceutical for Solid Tumor: Likelihood of Approval
Beroterkib is under clinical development by Taiho Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Tolinapant by Taiho Pharmaceutical for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
Tolinapant by Taiho Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Tolinapant by Taiho Pharmaceutical for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According...
Tolinapant by Taiho Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase...
Tolinapant by Taiho Pharmaceutical for Glioblastoma Multiforme (GBM): Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
Tolinapant by Taiho Pharmaceutical for T-Cell Leukemia: Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase II for T-Cell Leukemia. According to GlobalData, Phase...
Tolinapant by Taiho Pharmaceutical for Metastatic Colorectal Cancer: Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
Tolinapant by Taiho Pharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
Tolinapant by Taiho Pharmaceutical for Pancreatic Cancer: Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
Tolinapant by Taiho Pharmaceutical for Head And Neck Cancer: Likelihood of Approval
Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Head And Neck Cancer. According to...